More on AMRN
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $15.77 |
|
|||
| Open | $15.92 | ||||
| 52 Wk High | $3.65 | ||||
| 52 Wk Low | $1.24 | ||||
| Day High | $16.20 | ||||
| Day Low | $15.55 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 19,207 | ||||
- U.S. Supreme Court rules in favor of generic drugmaker Hikma in 'skinny label' patent dispute over Amarin heart drug vascepa
- Amarin presents analysis on risk-weighted apoB for cardiovascular patients
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated
- Amarin Corp. (AMRN) Misses Q1 EPS by 3c
- Amarin Reports 2026 First Quarter Financial Results
- Form 4 AMARIN CORP PLC\UK For: Apr 18 Filed by: Bonfiglio Patrice Eadon
- Form 4 AMARIN CORP PLC\UK For: Apr 18 Filed by: Cohen Paul
- Form 4 AMARIN CORP PLC\UK For: Apr 18 Filed by: O'Connor Oliver
- Form 4 AMARIN CORP PLC\UK For: Apr 18 Filed by: Horn Keith
- Form 4 AMARIN CORP PLC\UK For: Apr 18 Filed by: Sullivan Diane E.
Entities mentioned with AMRN
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Jefferies & Co | View Related Stories »
- Definitive Agreement | View Related Stories »
- JPMorgan | View Related Stories »
- AdCom | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- Options | View Related Stories »
- Show More...
